Several Substackers have been on the case of Paxlovid for leading to rebounds — essentially creating a scenario where individuals who may have otherwise stayed home and rested believe they are “cured” increasing transmission potential in the best case scenario. But snake oil is snake oil is snake oil regardless of the packaging. As it turns out, a recent study found that Molnupiravir may cause a similar, albeit more dire, effect.
We should not be too terribly surprised by instances of rebound infection beyond Paxlovid. Rebound infection from COVID-19 was a known phenomenon even before the mRNA inoculations.
However, what has been noted with Paxlovid appears to be that rebound infection is more common among the inoculated than the non-inoculated. Given that Paxlovid itself would work the same in both patient cohorts, that variance is a strong signal of immunological damage from the mRNA inoculations.
Elevated cases of rebound infection among COVID patients treated with Molnupiravir arguably sends the same signal.
Where the efficacy of the drug is inherently suspect, elevated instances of rebound infection among inoculated patients should be the expected scenario, so far as I can tell.
Molnupiravir was developed at Emory, who are in bed with the CDC, I'm sure there are absolutely no conflicts of interest.
It seems our entire healthcare system is one big grift.
Very interesting!!!
Air hammer
We should not be too terribly surprised by instances of rebound infection beyond Paxlovid. Rebound infection from COVID-19 was a known phenomenon even before the mRNA inoculations.
https://allfactsmatter.substack.com/p/cdc-issues-paxlovid-warning-but-what
However, what has been noted with Paxlovid appears to be that rebound infection is more common among the inoculated than the non-inoculated. Given that Paxlovid itself would work the same in both patient cohorts, that variance is a strong signal of immunological damage from the mRNA inoculations.
Elevated cases of rebound infection among COVID patients treated with Molnupiravir arguably sends the same signal.
Where the efficacy of the drug is inherently suspect, elevated instances of rebound infection among inoculated patients should be the expected scenario, so far as I can tell.